Merck & Co licenses Isis drug

Published: 29-Jun-2001


Isi Pharmaceuticals has licensed its preclinical Type II diabetes antisense drug candidate ISIS 113715 to Merck & Co. Preclinical data demonstrate activity in animal models of Type II diabetes.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like